Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 3/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12036812 | 0.98 | ALOX5 (0.41) | ALOX5PRKDCGGPS1PTGES2TNKS | |
| SCHEMBL12036926 | 0.86 | ALOX5 (0.34) | ALOX5PRKDC | |
| SCHEMBL10160798 | 0.83 | CA12 (0.36) | KDM1AMAOB | |
| SCHEMBL17705914 | 0.82 | ALOX5 (0.55) | ALOX5PRKDCGGPS1PTGES2PRMT5 | |
| SCHEMBL6374224 | 0.82 | ALOX5 (0.55) | ALOX5PRKDCGGPS1PTGES2PRMT5 | |
| SCHEMBL25132623 | 0.82 | ALOX5 (0.55) | ALOX5PRKDCGGPS1PTGES2PRMT5 | |
| SCHEMBL74451 | 0.82 | ALOX5 (0.55) | ALOX5PRKDCGGPS1PTGES2PRMT5 | |
| SCHEMBL6373554 | 0.82 | ALOX5 (0.55) | ALOX5PRKDCGGPS1PTGES2PRMT5 | |
| SCHEMBL75968 | 0.82 | ALOX5 (0.55) | ALOX5PRKDCGGPS1PTGES2PRMT5 | |
| SCHEMBL15496371 | 0.82 | ALOX5 (0.55) | ALOX5PRKDCGGPS1PTGES2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120018710-A1 | NOVEL POLYMERIZABLE MONOMER AND POLYMER OF THE POLYMERIZABLE MONOMER, AND MATERIAL FOR ORGANIC DEVICE, HOLE INJECTION/TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT ELEMENT EACH COMPRISING THE POLYMER | IDEMITSU KOSAN CO., LTD. | 2012-01-26 | — | — | US | disclosed |
| US-20120018710-A1 | NOVEL POLYMERIZABLE MONOMER AND POLYMER OF THE POLYMERIZABLE MONOMER, AND MATERIAL FOR ORGANIC DEVICE, HOLE INJECTION/TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT ELEMENT EACH COMPRISING THE POLYMER | IDEMITSU KOSAN CO., LTD. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120018710-A1 | NOVEL POLYMERIZABLE MONOMER AND POLYMER OF THE POLYMERIZABLE MONOMER, AND MATERIAL FOR ORGANIC DEVICE, HOLE INJECTION/TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT ELEMENT EACH COMPRISING THE POLYMER | EPB41, EPB41L2, AR | ALOX5 1528/4885PRKDC 4837/4885GGPS1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.